B. Braun Medical Inc. recalls 0.9% Sodium Chloride

March 7, 2022

As reported by the U.S. Food and Drug Administration (FDA), B. Braun Medical Inc. (B. Braun) is voluntarily recalling five (5) lots of 0.9% Sodium Chloride for Injection USP 250ML in Excel within the United States to the hospital/user level. The voluntary recall has been initiated due to fluid leakage or low fill volume of the respective containers.

The biggest risk with a slow leak in any intravenous solution preparation is a break in sterility which poses a risk for the patient being exposed to a bacterial or fungal infection. There is a remote probability this could lead to bloodstream infection. B. Braun has not received any reports of adverse events related to this recall.

0.9% Sodium Chloride for Injection USP in Excel is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% Sodium Chloride Injection USP in Excel is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells.

The product was distributed Nationwide within the United States to domestic distributors.

FDA News Release

ID 204561283 | Abstract © Dimitris Barletis | Dreamstime.com
dreamstime_xl_204561283
ID 366090882 © Zhanna Hapanovich | Dreamstime.com
dreamstime_xl_366090882
ID 179810040 © Josepalbert13 | Dreamstime.com
cdc_3
ID 150983874 © Adonis1969 | Dreamstime.com
dreamstime_xl_150983874
ID 241576013 © Josepalbert13 | Dreamstime.com
cms_2